Fibrocell Science (NASDAQ:FCSC) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Fibrocell Science (NASDAQ:FCSC) from a sell rating to a hold rating in a research note published on Monday morning, Zacks.com reports.

According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “

FCSC has been the topic of several other reports. ValuEngine cut shares of Fibrocell Science from a hold rating to a sell rating in a report on Saturday, June 22nd. HC Wainwright restated a buy rating and set a $22.00 price target on shares of Fibrocell Science in a report on Thursday, March 28th.

NASDAQ FCSC opened at $1.86 on Monday. Fibrocell Science has a twelve month low of $1.45 and a twelve month high of $3.28. The company has a debt-to-equity ratio of 0.85, a quick ratio of 3.59 and a current ratio of 3.59. The stock has a market cap of $18.25 million, a PE ratio of -1.28 and a beta of 1.75. The business’s 50 day moving average price is $1.96.

Fibrocell Science (NASDAQ:FCSC) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.07). On average, equities research analysts expect that Fibrocell Science will post -1.31 earnings per share for the current fiscal year.

An institutional investor recently raised its position in Fibrocell Science stock. Virtu Financial LLC grew its stake in shares of Fibrocell Science Inc (NASDAQ:FCSC) by 90.7% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 39,864 shares of the company’s stock after acquiring an additional 18,958 shares during the period. Virtu Financial LLC owned 0.41% of Fibrocell Science worth $77,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 28.04% of the company’s stock.

Fibrocell Science Company Profile

Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.

Featured Article: Understanding the different types of bonds

Get a free copy of the Zacks research report on Fibrocell Science (FCSC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.